The Centers for Disease Control and Prevention today released updated interim clinical guidance for U.S. health care providers evaluating and caring for patients with lung injury associated with use of electronic cigarette or vaping products. The interim guidance offers clinicians a framework for their initial assessment, evaluation, management and follow-up of people with symptoms associated with the illness. It advises close follow-up of these patients, as some patients who initially had mild symptoms experienced a rapid worsening of symptoms within 48 hours. CDC also released a report summarizing national surveillance data describing clinical features of more recently reported cases and refines CDC’s public health recommendations.
 
Yesterday, CDC updated the number of people with confirmed or probable lung injuries associated with e-cigarette use or vaping products to 1,299 in 49 states and the U.S. Virgin Islands, including 26 deaths. CDC and the Food and Drug Administration continue to investigate the cause of the injuries. All of the patients reported using electronic cigarette or vaping products, and most have used products containing tetrahydrocannabinol (THC). CDC continues to encourage clinicians to report possible cases to their local or state health department; and the public to consider refraining from vaping products, especially those containing THC, while the investigation continues. For additional information and resources for health care providers, including a poster for clinical settings, visit www.cdc.gov

Related News Articles

Headline
The Food and Drug Administration April 29 issued a final rule that would phase out its general enforcement discretion approach for most laboratory developed…
Headline
In clinical trials involving 220,000 patients at 59 HCA Healthcare hospitals, algorithm-driven computerized alerts helped clinicians better identify the…
Headline
Commenting April 12 on a proposed rule to strengthen oversight of accrediting organizations, AHA told the Centers for Medicare & Medicaid Services it…
Headline
The Food and Drug Administration’s proposal to regulate laboratory developed tests would undermine innovation and reduce access to effective and appropriate…
Chairperson's File
 Fostering a culture of innovation and safety that prioritizes communication and teamwork to deliver safe, world-class care to patients and also protects…
Headline
The Food and Drug Administration’s proposal to regulate laboratory developed tests would undermine innovation and reduce access to effective and appropriate…